EASME

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Neuro Device Group S.A. is a Polish med-tech company, established in 2008 and based in Warsaw, specializing in the development and manufacturing of medical devices aimed at addressing neurological disorders. The company's product lineup includes Neuro Device Camri, a diagnostic recording camera for MRI scanners; Neuro Device Scent, which measures neuronal reactions to scents; and Neuro Device Tacti, a stimulator used in preoperative fMRI diagnostics to localize brain sensomotoric areas. In addition to its proprietary devices, Neuro Device Group also distributes a range of high-quality neurological products and medical devices from leading global manufacturers, encompassing areas such as eye tracking, rehabilitation, virtual reality, and fMRI. The company's ongoing mission is to enhance neurological research and improve patient outcomes through innovative technologies.

BIOsens Inc. specializes in developing biosensors for the rapid quantitative diagnostics of food toxins, particularly mycotoxins. The company offers a testing device that allows for easy sample preparation and delivers results within 15 minutes. These results are stored in the cloud, utilizing Internet of Things (IoT) technology. By providing efficient and reliable testing solutions, BIOsens aims to enhance food safety and help consumers trust the safety of their food products.

Founded in London in 2017, Limbic specializes in developing software solutions for mental health. They create AI-driven agents to assist in patient intake, triage, screening, and therapy, aiming to enhance the efficiency of healthcare providers and improve patient outcomes.

Racefox, headquartered in Stockholm, Sweden, specializes in digital coaching for running and cross-country skiing. Utilizing a combination of biomechanics research, sports science, data science, and AI, the company's application provides personalized training plans and real-time performance metrics. By analyzing users' movements and identifying potential issues, Racefox helps enhance performance and prevent injuries, catering to both elite athletes and recreational enthusiasts seeking to improve their skills and maintain a healthy lifestyle.

Clover Bioanalytical is a bioinformatics company focused on developing software solutions for bioanalytical chemistry and clinical diagnostics, particularly utilizing mass spectrometry. Established by a team of Ph.D. graduates with extensive experience in both research and business, the company excels in providing advanced data processing capabilities and statistical analysis in the biomedical field. Clover's expertise encompasses mass spectrometry applications, medical image processing, and both univariate and multivariate statistical analyses, making it adaptable to a variety of needs within the healthcare sector. The company emphasizes a customer-oriented approach, tailoring its systems to meet client goals and ensuring scalability. Furthermore, Clover aims to address significant scientific challenges in collaboration with hospitals, research centers, and biotechnology firms, employing artificial intelligence to aid in the rapid identification of microorganisms and enhance diagnostic processes.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

FGen GmbH is a Swiss company founded in 2011 as a spin-off from ETH Zurich, based in Basel. It specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries, facilitating the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in biotech, life sciences, and pharmaceuticals to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on optimizing microbial strains for biotechnological applications by integrating proprietary screening technology with biological engineering tools. This enables clients to achieve efficient and cost-competitive bioproduction of chemicals and proteins.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

CardiacSense Ltd., founded in 2012 and based in Caesarea, Israel, develops innovative medical wearable devices aimed at monitoring heart arrhythmias and other critical health metrics. The company's FDA and CE certified medical watches and wristbands provide continuous, long-term, ambulatory, and non-invasive monitoring of vital functions, including heart rate, pulse rate, respiratory rate, core temperature, oxygen saturation, and blood pressure. Utilizing advanced PPG technology, CardiacSense's devices enable accurate real-time diagnostics for various medical conditions such as atrial fibrillation, hypertension, chronic obstructive pulmonary disease, heart failure, sleep apnea, and infections like COVID-19. By focusing on the prevention and early detection of cardiac events, CardiacSense aims to enhance healthcare delivery and improve patient outcomes.

MyoSwiss is a Swiss medtech company that develops robotic and textile technology to help people with muscle weakness regain mobility and independence. The company manufactures the Myosuit and Myofit training devices used in rehabilitation and physiotherapy to improve walking and running ability. It offers individualized training plans, intensive and activity-based training, and performance tracking, along with a multifunctional training device that provides an additional layer of muscle support for mobility-impaired patients. Founded in 2017, the company is based in Zurich, Switzerland.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

liberDi is an Israeli company that specializes in developing portable automatic peritoneal dialysis systems for patients with end-stage renal disease. The company has created a comprehensive Digital Dialysis Clinic that enables patients to manage their own dialysis care with the assistance of an Intelligent Dialysis Assistant and remote medical supervision. This innovative self-care system allows patients to perform dialysis conveniently from various locations, such as their homes or while traveling, thereby enhancing their quality of life. Founded in 2014, liberDi aims to transform the traditional dialysis model by providing a safe, patient-friendly alternative to in-clinic care. The company's technology not only empowers patients but also helps clinics optimize their operations, improve service quality, and reduce costs, establishing a holistic platform for renal patients and their caregivers.

PEARlabs, founded by Dominic Zerulla in 2017, is a technology company focused on commercializing advanced imaging solutions for scientific research. It specializes in super-resolution imaging beyond the diffraction limit of visible light using proprietary electronically addressable photonic chips. Additionally, PEARlabs offers novel nanoscale functional materials. The company leverages over two decades of international research expertise in plasmonics, nano-optics, and nano-physics to enhance biomedical and subcellular analysis for its clients.

Espansione Group is a medical technology company specializing in the development and distribution of innovative, non-invasive devices for ophthalmology. Their product portfolio includes proprietary photobiomodulation devices, light therapy systems using red, blue, and ultraviolet light, and diagnostic tools for eye screening. These solutions are designed to enhance patient outcomes by leveraging advanced, science-driven therapies, primarily serving the ophthalmology field.

Probiomedica is a company focused on developing innovative biomedical devices that integrate engineering, biology, photonics, and robotics for health and personal care applications. The company specializes in creating small swallowable capsules designed to emit light at specific wavelengths, utilizing the principles of Photodynamic therapy. This technology aims to enhance the photo-killing of harmful bacteria such as Helicobacter pylori, which is associated with conditions like gastritis, peptic ulcers, and gastric cancer. By employing these advanced photonic techniques, Probiomedica seeks to offer effective treatments that minimize reliance on pharmaceuticals and reduce the risk of drug-related side effects, thereby improving patient outcomes in the realm of gastrointestinal health.

Hedia is a health technology company that has created an artificial intelligence-based application aimed at assisting individuals with type 1 and type 2 diabetes. The application functions as a personal diabetes assistant, monitoring users' carbohydrate intake and exercise habits to provide tailored insulin recommendations. By analyzing individual patterns and behaviors, Hedia's solution aims to simplify daily management of diabetes, enhancing the quality of life for its users through informed insulin treatment.

BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

Microbium is an innovative research and development company specializing in microbiological detection protocols tailored for specific industrial applications. Founded to address the pressing challenges posed by microbial contamination, Microbium collaborates closely with national laboratories and analytical organizations in Russia, Denmark, and Slovenia. The company develops advanced electronic devices that automate the detection and counting of harmful microorganisms, such as E. coli and coliforms, in drinking water and various industrial products. Additionally, Microbium employs a bioremediation process to effectively eliminate these microorganisms from water supply systems and production lines, thereby helping clients reduce contamination hotspots, lower production costs, and minimize their environmental impact.

Axiamo GmbH, founded in 2015 and based in Nidau, Switzerland, specializes in the development and manufacturing of motion sensor technology aimed at measuring key parameters of physical performance. The company offers advanced motion sensors that provide detailed data on acceleration, rotation, magnetic fields, air pressure, and temperature. These sensors enable athletes to receive objective feedback, thereby enhancing their training and performance. Additionally, Axiamo provides scientifically validated running sensors that analyze running mechanics, further supporting athletes in optimizing their performance.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of advanced hearing solutions aimed at addressing various levels of hearing impairment. As a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic in Tübingen, Vibrosonic focuses on innovative technologies that enhance the auditory experience for users. The company has created hearing contact lenses that utilize microsystem technology and a piezoelectric principle, enabling sound transmission through vibrations directly to the eardrum. This approach offers a discreet alternative to traditional hearing aids, improving comfort and usability for individuals with hearing loss.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

TomoWave is a company focused on developing innovative imaging technologies for clinical medicine and preclinical research. Utilizing its proprietary optoacoustic and laser ultrasonic imaging modalities, TomoWave aims to enhance cancer detection, guide medical interventions, and monitor the effectiveness of cancer therapies. The company's technology, which captures images by "listening to the sound of light," allows for highly detailed visualization of tissues, particularly in relation to vascular and blood-related conditions. Founded by Dr. Alexander Oraevsky, a pioneer in biomedical optoacoustics, TomoWave has a strong emphasis on generating intellectual property and advancing it from concept to validated clinical prototypes. The company is committed to bringing its technologies to market through appropriate regulatory certifications, thus contributing to improved diagnostic capabilities in healthcare.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

Segmentum Imaging is a brand new app allowing you to count samples more quickly than traditional methods have previously allowed, whilst releasing you from the confines of the lab. Do your work conveniently, increasing your output and decreasing your time spent on repetitive actions. The adoption of digital pathology has been increasing dramatically. It is being used for more convenient diagnosis, easier sharing of images between consultants, large-scale collection for research purposes and in the creation of online virtual archives, critical in teaching and multi-centre research. Whilst the tools for researchers to utilise digital images have become very advanced, they are often very expensive and are commonly based in individual laboratories. This can easily result in considerable bottlenecks in use and limitations of access often lead to these facilities being simultaneously very costly but under-utilised.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

Brain Stimulation AB, established in 2011 in Sweden, focuses on providing innovative assessment and rehabilitation solutions for individuals recovering from strokes and traumatic brain injuries. The company leverages research on brain plasticity to develop advanced rehabilitation strategies for cognitive impairments, including attention deficits such as Spatial Neglect. By addressing the critical need for effective rehabilitation in stroke, dementia, and other degenerative brain conditions, Brain Stimulation combines cutting-edge technology with scientific insights to create individualized rehabilitation care. Their approach emphasizes remote accessibility and a motivating environment, enabling patients to strengthen neuronal connections and enhance recovery outcomes.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Pre Diagnostics is a Norwegian diagnostic company specializing in the development of innovative in-vitro diagnostic (IVD) products aimed at the early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company leverages a proprietary approach that focuses on identifying systemic responses in macrophages unique to specific diseases, which can be accurately measured through blood samples. By developing blood-based biomarkers and utilizing established technologies, Pre Diagnostics provides healthcare professionals with actionable insights that enhance the early diagnosis of Alzheimer's. The company is committed to creating patient-friendly diagnostic solutions that deliver value to patients, partners, and investors alike.

SensoGenic Inc., established in 2016 and headquartered in Ness Ziona, Israel, specializes in developing diagnostic biosensors for food allergen detection. The company offers portable, handheld devices and digital analyzers designed for consumers, enabling them to test food items for allergens on-the-go. SensoGenic's innovative technology uses biosensors to detect allergens without physical contact, providing users with real-time results via a mobile application. This allows individuals with food allergies to safely consume meals at restaurants or social gatherings by avoiding allergic reactions.

Founded in 2005, Medfield Diagnostics specializes in manufacturing diagnostic instruments to enhance clinical outcomes. The company is renowned for its research on the application of microwave technology in stroke diagnostics, with notable products including Strokefinder.

Nateo Healthcare is a Toulouse, France-based medical technology company that designs, develops, and manufactures connected devices and software for obstetrics and gynecology. Founded by obstetricians, gynecologists and medical technology specialists, the company focuses on portable fetal monitoring solutions, including compact mobile fetal heart and uterine activity monitoring systems, and remote patient monitoring for maternity care. Its products enable continuous fetal heart rate and uterine activity assessment, support telemonitoring for home use or hospital settings, and aim to optimize bed utilization in maternity wards while enhancing patient well-being through more flexible care. By integrating wireless connections and real-time data, Nateo Healthcare seeks to provide clinicians with mobile, connected CTG monitoring capabilities and to expand access to monitoring in hospitals and at home.

ODI Medical is a developer of advanced medical technology focused on the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's innovative devices streamline the collection of microvascular data, facilitating a variety of clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, early detection of evolving sepsis, and monitoring chronic wounds. Additionally, ODI Medical's technology supports mass screening for infectious conditions such as Ebola, bird flu, and epidemic meningitis. By utilizing non-invasive methods, the company enables medical researchers to enhance patient therapy through a better understanding of microcirculation.

Lucine is a company focused on improving patient health, primarily targeting pain management. It develops a mobile health application that offers a digital therapeutic solution designed to relieve pain within five minutes through analgesic neurostimulation. The application employs advanced algorithms to measure and analyze pain by utilizing facial, vocal, and postural recognition. This technology allows for personalized treatment, as it instantly adapts to each patient's specific needs. The application provides a variety of techniques to alleviate pain symptoms, including exercises, relaxation methods, art therapy, and meditation, empowering patients with chronic pain to manage their conditions effectively from home.

Raylytic GmbH is a software development company specializing in automated medical image analysis and clinical data extraction. Founded in 1999 and headquartered in Leipzig, Germany, with additional offices in Magdeburg, Raylytic offers the UNITY platform, which provides a fully integrated solution for clinical trial management and medical data collection. This web-based platform streamlines the setup and execution of clinical data collection tasks, including the management of case report forms and patient-reported outcome measures, while employing advanced algorithms for the precise analysis and quantification of radiological images. Raylytic's services encompass a range of activities, including clinical trials for medical devices, independent qualitative analysis, development of radiographic protocols, quality assurance, data management, and statistical reporting. The company's innovative approach combines industrial and medical image processing with machine learning, enabling efficient and accurate evaluation of medical images for evidence-based medicine and regulatory compliance.

Healthplus.ai is a technology company that specializes in predictive analytics for surgical patient care. It repurposes electronic health record data to forecast potential complications following surgery, empowering healthcare professionals to proactively manage patient recovery. By identifying risks early, Healthplus.ai helps reduce post-operative issues, enhance clinical outcomes, and lower healthcare costs.

eLive Ecosystem specializes in developing innovative solutions aimed at preventing long-term diseases through advanced technology. The company has created an artificial intelligence-based medical device specifically designed for the self-measurement of sleep apnea, addressing diagnostic gaps and enhancing treatment monitoring. By integrating medicine, genomics, and advanced sensor technology, eLive aims to alleviate the pressures on healthcare systems caused by demographic changes and aging populations. Their platform focuses on enabling healthcare professionals to efficiently and cost-effectively manage disease prevention and treatment, ultimately improving patient outcomes on a global scale.

Dytective is the scientifically validated reference tool for detection and improvement of skills related to dyslexia. Dytective combines two scientifically validated tools developed by Change Dyslexia. In only 15 minutes, through a series of tests, according to your age and abilities, Dytective Test detects if you are at risk of having dyslexia. With DytectiveU you will improve your reading and writing skills while having fun playing.

ControlNano is a spin-off company leaded by a group of professionals with high expertise in the field of health risk assessment related to the exposure of nanoparticles in industrial facilities and urban environments. They design and manufacture highly reliable and robust devices to provide accurate information on the concentration levels of nanoparticles and respirable dust in air.

Enzymlogic is a specialized company focused on enzymology and protein science, delivering innovative analytical solutions to the pharmaceutical and biotech sectors. They aim to enhance the drug discovery and development process, ultimately improving patient quality of life through safer and more effective therapeutics. By offering services that help determine kinetic profiles in drug interactions, Enzymlogic provides critical insights into the efficacy and safety of potential medications. Their mission is to support clients in maximizing their return on investment while fostering the development of groundbreaking therapies. Enzymlogic aspires to be a leading reference for organizations engaged in drug discovery through rational analysis approaches.

Waterscope is a not-for-profit impact-defined company based in Cambridge. Waterscope is a Cambridge University spin-out developing easy-to-use, rapid water testing microscopes capable of identifying bacterial presence in drinking water. Their bacterial imaging device can identify specific bacterial micro-colonies in less than 6 hours, four times faster than current gold-standard portable systems. Their system is automated, not requiring significant user training. Using image recognition software, bacterial colonies can be automatically identified and counted. Once data is collected the bacterial imaging device will automatically upload and disseminate results for mapping or intervention. THeir novel bacterial cartridge simplifies bacterial testing eliminating the need for a central lab and significant user training.

BioSpeedia develops and manufactures a vitro diagnostics rapid test kits and ELISA kits for medical professionals.

Biom'Up S.A. is a French company specializing in the development and commercialization of innovative hemostatic products and absorbable medical devices based on patented biopolymer and collagen technologies. Founded in 2005 and headquartered in Saint-Priest, France, Biom'Up designs and manufactures medical devices aimed at improving surgical outcomes across various specialties, including orthopedic, spinal, cardiac, general, and maxillofacial surgeries. Its flagship products, such as HEMOBLAST bellows and associated laparoscopic applicators, are clinically proven to enhance patient healing by facilitating guided regeneration of soft tissues and bone. The company markets its products primarily in Europe and the United States, contributing significantly to the field of biosurgery.

BioMensio develops smart handheld devices for rapid, on-site detection of multiple biological targets. Its core technology enables label-free assays and facilitates development of new bio-screening applications. The company's products include BioMensio devices and a novel miniaturized microarray platform, serving point-of-care, food safety, and bio-security applications.

Cogvis specializes in computer vision, machine learning, and 3D data analytics to enhance patient safety and caregiver productivity. Founded in 2007, it provides a privacy-protecting AI-based system that monitors patients autonomously, preventing falls and other critical incidents while reducing administrative workload for nurses by up to 30%.

Mecwins develops nanotechnological platforms for sensitive immunoassays, focusing on applications in oncology, cardiovascular disease, and infectious diseases. Their technology improves healthcare outcomes for at-risk populations.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

The WLTS laboratory is organized to take samples of asbestos (air and material) and to analyze the samples taken.

PlanDomino is a developer of digital lab scheduling software designed to optimize resource allocation and manage testing workflows efficiently. The company's platform leverages advanced technology to facilitate visual management, connecting laboratories with their operations and supply chains. By enabling effective allocation of tasks for analysts, PlanDomino enhances productivity and ensures end-to-end visibility of samples throughout the testing process. Its fully digitized system not only reduces costs and lead times but also improves laboratory productivity by an average of 30 percent, all while requiring minimal training and no extensive consultancy services for maintenance. PlanDomino's solution fosters collaboration between laboratory functions, operations, and supply chains, breaking down silos and improving overall efficiency.

Biocompatibility Innovation (BCI), established in 2014 in Padua, Italy, specializes in biotechnologies for biomedical applications. The company develops and manufactures highly biocompatible implantable prostheses, both biological and polymeric, using its proprietary FACTA® and PROTEGO technologies. These innovations extend the lifespan of bioprostheses and enhance the biocompatibility of implantable medical devices. BCI also provides third-party testing services and develops new proprietary treatments. Led by experienced researchers and managers in biotech and biomedicine, BCI aims to improve clinical management, patient quality of life, and lower healthcare costs.

DermoSafe is a Swiss company founded in November 2012 by Philippe Held, located in Cheseaux, Switzerland. The company specializes in innovative products and services aimed at the early detection and management of melanoma. DermoSafe manufactures medical devices that capture high-definition dermoscopic images of moles and pigmented lesions, facilitating a straightforward process for general practitioners. Through a secure web application, practitioners can enter patient data and send images to dermoscopy specialists for analysis. These specialists provide their assessments in documented electronic reports, enabling healthcare professionals to identify melanoma at an early stage and effectively manage treatment.

Bambi Medical is a MedTech company founded in November 2015 by Sidarto and Fabio Bambang Oetomo, focused on enhancing the care of pre-term infants. The company aims to reduce pain and stress in these vulnerable patients while fostering stronger parent-child bonding. To achieve this, Bambi Medical designs, develops, and manufactures innovative products specifically for Neonatal Intensive Care Units. One of its key offerings is a wireless health monitoring device that tracks vital signs such as breathing, heart rate, and temperature. This device allows for maximal skin-to-skin contact between infants and their parents, and it measures critical health data without the discomfort associated with adhesive electrodes, thereby facilitating effective monitoring of the baby's condition.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

Filterlex Medical is a medical device company focused on cardiovascular embolic protection. It develops embolic protection devices to reduce the risk of stroke and other embolic complications during catheter-based structural heart procedures, including transcatheter aortic valve implantation. Its CAPTIS full-body embolic protection device is designed for intuitive deployment and retrieval and is compatible with multiple catheter sizes, enabling integration into existing workflows. The company aims to improve patient safety during minimally invasive heart valve replacement procedures. It was founded in 2015 and is based in Yokneam, Israel.

Founded in 2014 and headquartered in Jena, Germany, Preventicus develops certified medical device software for smartphones and smartwatches. Its primary product, Preventicus Heartbeats, identifies atrial fibrillation for stroke prevention by analyzing patients' vital parameters, enabling early detection of lifestyle-related illnesses.

RegStem is an early-stage biopharmaceutical company focused on repurposing existing molecules and developing new treatments within the regenerative medicine sector. The company specifically targets rare muscle and blood diseases that present significant unmet medical needs. Its research and development efforts are centered on innovative molecules intended for human therapies, including the repurposing of drugs aimed at reconstituting and repairing bone marrow during acute aplasia and promoting skin healing after scarring. By stimulating and controlling the differentiation of stem cells, RegStem aims to provide effective solutions for patients suffering from chronic skin conditions and other serious health issues.

SamanTree Medical SA is a Swiss medical microscopy device company specializing in advanced micro-optics based digital microscopy systems designed for research, diagnostic, and surgical applications. Founded in 2014 and located in Ecublens, Switzerland, the company focuses on enhancing cancer treatment through innovative imaging solutions. Its flagship product is a surgical digital microscope that enables real-time visualization of the cellular structure of living tissue, allowing surgeons to accurately assess tumor margins during procedures. This technology facilitates improved surgical treatment decisions, enhances resection accuracy, and helps reduce re-operation rates, ultimately lowering the overall costs associated with surgical interventions. By providing histology-grade confidence and full margin control during lumpectomies, SamanTree Medical aims to significantly improve patient care and outcomes in cancer surgery.

Neurosteer develops a wearable device and cloud-based system for early detection and effective treatment of neurological disorders. It uses an adhesive forehead strip connected to a pocket-sized device, transmitting data wirelessly for real-time brain activity analysis. The solution aims to provide affordable screening, continuous patient monitoring, and optimized neurostimulation and drug selection, improving neurological treatment outcomes.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

Dart Diagnostics is a diagnostic company focused on enhancing diagnostic assays to provide better and earlier results in various fields, including clinical diagnostics, water analysis, and food safety. The company specializes in the development of bio-inspired polymers for nanotechnology, which amplify the signal from immunoassays. This innovation enables healthcare professionals to achieve more accurate results efficiently, ultimately saving time, reducing costs, and improving patient outcomes. Founded by scientists who are acutely aware of the challenges in detection, Dart Diagnostics aims to address the widespread need for improved diagnostic solutions across multiple sectors.

Avia-GIS NV is a Belgian SME founded in 2001 that specializes in spatial risk mapping and modelling as a basis for the development of tailored spatial decision support systems applied to public-, animal- and crop health and integrated pest management. Their company has a unique market position. Only few companies operate in their domain and developed such close contacts with the industrial, institutional and academic world. They have offices in Belgium, South Africa and Guadeloupe, and are active in more than 50 countries.

CytaCoat is a private Swedish company based in the Karolinska Institutet Science Park in Solna, Stockholm. Founded by researchers from the Karolinska Institute and the Royal Institute of Technology, the company focuses on developing a proprietary antibacterial coating technology for medical devices. This innovative coating is designed to combat healthcare-associated infections by repelling problematic pathogenic bacteria without the use of antibiotics, thus minimizing the risk of antibiotic resistance. CytaCoat's technology is characterized by its stability under varying pH and ionic conditions, ensuring safety and effectiveness. The company operates a fully equipped laboratory for microbiological evaluation and optimization of its technology, and it has established collaborations with clinical partners such as the Karolinska University Hospital. Additionally, CytaCoat engages with regulatory consultants and clinical research organizations to guide its product development and commercialization efforts.

liberDi is an Israeli company that specializes in developing portable automatic peritoneal dialysis systems for patients with end-stage renal disease. The company has created a comprehensive Digital Dialysis Clinic that enables patients to manage their own dialysis care with the assistance of an Intelligent Dialysis Assistant and remote medical supervision. This innovative self-care system allows patients to perform dialysis conveniently from various locations, such as their homes or while traveling, thereby enhancing their quality of life. Founded in 2014, liberDi aims to transform the traditional dialysis model by providing a safe, patient-friendly alternative to in-clinic care. The company's technology not only empowers patients but also helps clinics optimize their operations, improve service quality, and reduce costs, establishing a holistic platform for renal patients and their caregivers.

Rqmicro is a Swiss company based in Zurich, founded in 2013, that specializes in pathogen separation and detection technology. The company has developed proprietary reagents and instruments for rapid microbiological testing, which provide accurate results in under one hour. Rqmicro's technology is utilized for the rapid assessment of water and food safety, enabling clients to detect dangerous pathogens effectively. By delivering quantitative data on contamination, Rqmicro's solutions enhance the overall safety of water and food products, addressing critical public health concerns.

AXO Science develops advanced diagnostic tools that combine forensic and medical applications. Its flagship product is a multi‑parameter testing platform that uses a polymer‑based biochip with grafted oligonucleotide probes to deliver rapid, molecular‑level characterizations. The technology supports forensic laboratories and clinical diagnostics, enabling precise identification of biological markers and improving public health outcomes.

BioBlocks is a collaborative medicinal chemistry research organization that specializes in drug discovery, guiding clients from initial lead discovery to identifying development candidates. The company offers a comprehensive drug discovery platform that includes a fragment library and compound database, assisting clients in identifying viable new chemical entities for biological pathways. BioBlocks also provides preclinical development and clinical trial management services, enabling pharmaceutical companies to generate and optimize quality clinical candidates. By fostering collaboration with clients, BioBlocks aims to enhance the effectiveness, speed, and reliability of drug discovery programs, ultimately advancing compounds into clinical trials.

MEDIKURA Digital Health GmbH, founded in 2017 and based in Munich, Germany, specializes in developing a platform focused on drug safety issues and analysis. The company offers a suite of products, including MEDIKURA Capture, which allows users to report side effects online; MEDIKURA Insights, which provides insights into drug safety and customer satisfaction; and MEDIKURA Guide, designed to help users understand the risks and benefits of their medications. Catering primarily to the pharmaceutical and insurance industries, MEDIKURA aims to enhance drug safety and improve the overall understanding of medication-related risks.

Corti is an artificial intelligence company specializing in medical triaging through a voice-based platform that analyzes patient interviews. The platform is designed to enhance healthcare providers' efficiency by preparing case files prior to patient consultations and suggesting relevant questions to ask. Utilizing advanced speech recognition and natural language processing technologies, Corti's system comprehensively understands patient situations, which helps reduce errors and increase decision-making accuracy during medical consultations. Trusted by leading healthcare providers, Corti seamlessly integrates into existing workflows, aiming to improve patient interactions and ultimately save more lives.

LifeTag is a Portuguese technology startup dedicated to the research and development of non-invasive health monitoring technologies. The company focuses on creating diagnostic markers that assess metabolism and diagnose various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. LifeTag's innovative approach includes evaluating intestinal permeability to enhance the accuracy of chronic disease diagnoses, offering healthcare professionals a means to identify conditions more precisely without causing discomfort to patients. By prioritizing non-invasive methods, LifeTag aims to improve patient experiences while contributing to more effective healthcare solutions.

Invent Medical's mission is helping people. New technology will constantly disrupt and change the medical field. They apply digital technologies to invent, develop and design a new generation of custom-made orthotic & prosthetic products so patients can experience better treatment outcomes.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.

EIO Biomedical is a biotechnology company based in Nazareth, Israel, focused on developing a medical device aimed at preventing post-surgical adhesions. Established in 2016, the company has created a spray containing essential blood clotting proteins that promotes targeted clotting at the wound site. This innovative product alters the formation of the fibrin network by cross-linking fibrin to establish a barrier against cell adhesion. As a result, it enables surgeons to conduct both laparoscopic and open surgeries with reduced concern for significant surgical complications. EIO Biomedical has received financial backing from NGT3 VC and the Israeli Office of Chief Scientist, highlighting its potential impact in the field of surgical procedures.

Grundium Ltd, established in 2015 and headquartered in Tampere, Finland, specializes in imaging and multi-camera solutions. The company caters to diverse industries such as transportation, biotechnology, and professional imaging, offering end-to-end solutions that include hardware, software, and user services. Grundium's core expertise lies in providing high-quality, portable digital microscope scanners designed for live telepathology consultations, enabling real-time, high-resolution image transmission between surgeons and pathologists, regardless of location. This innovative technology enhances diagnostic pathology reach and quality while reducing time and costs. Additionally, Grundium provides multi-camera solutions for the transportation industry, capable of withstanding harsh environmental conditions, and offers microscopic imaging platforms for various applications.

Chino.io is a technology company specializing in data security and compliance for digital health applications and medical devices. It offers a modular IT platform that addresses security and privacy challenges, ensuring compliance with stringent regulations such as EU GDPR and HIPAA. By utilizing Chino.io's platform, digital health innovators can eliminate data management risks, reduce compliance costs, and focus on developing medical-grade software.

Biomode is a Portuguese startup based in Caldas das Taipas that specializes in the development of rapid and accurate molecular diagnostic tests for identifying pathogens in the food, environmental, and life science sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridisation (PNA-FISH) technology, Biomode's diagnostic kits eliminate the need for DNA extraction or amplification, making them less susceptible to inhibitory compounds and capable of detecting only viable bacterial cells. The company is preparing to launch its first product, Probe4Salmonella®, for the detection of Salmonella in food samples, with plans to follow up with kits for Listeria monocytogenes and E. coli O157:H7. Additionally, Biomode has developed Probe4Pylori®, a kit for the rapid identification of clarithromycin resistance in H. Pylori strains, which is currently seeking investigational device exemption from the FDA to initiate field trials. Founded by a team of researchers from the universities of Minho and Porto, Biomode stands out as one of the few groups globally capable of designing PNA-FISH probes targeting specific pathogens.

BioAxial is a company focused on advancing fluorescence microscopy technology to enhance the extended imaging of live cells. Its innovative approach centers on the development of optical modules that serve as add-ons for commercial microscopes, allowing for high-resolution imaging with a resolution of less than 100 nanometers. The company's unique fluorescence microscopy workflow utilizes a beam shaper to create localized light patterns, which helps minimize photo-toxicity and photo-bleaching during the imaging process. This enables clinicians and physicists to obtain detailed observations of biological samples while preserving their integrity. BioAxial holds several patents for its technologies, underscoring its commitment to innovation in the field of microscopy.

GlyCardial Diagnostics S.L. is a biotechnology company based in Barcelona, Spain, established in 2017 as a spin-off from the Catalan Institute of Cardiovascular Sciences and the Spanish National Research Council. The company specializes in developing point-of-care diagnostic devices aimed at detecting abnormal levels of the Apo J-Glyc protein in blood, serving as a biomarker for the early diagnosis of myocardial ischemia. GlyCardial's innovative technology seeks to identify patients at risk of experiencing ischemic attacks before they occur, addressing significant unmet medical needs in cardiovascular care. By facilitating timely healthcare decisions, the company's solutions aim to reduce the risk of irreversible myocardial damage and heart failure, ultimately improving patient outcomes following ischemic events.

BioProbe Diagnostics (BPD) is a company established in 2017 as a spin-out from NUI Galway. It specializes in commercializing proprietary Nucleic Acid Diagnostics technologies for detecting and identifying microbial contaminants in environmental and industrial sectors, holding worldwide licenses for these applications. BPD has collaborated closely with NUI Galway to transition this technology from the lab to the market. The company's team includes scientists, inventors, and a business manager with proven experience in product development. Currently, BPD is focused on launching its initial NAD product, Bio-Lp-1, which offers advanced capabilities for Legionella testing.

Macro Array Diagnostics is a Vienna-based MedTech company. They develop, produce and distribute tests, instruments and software for allergy diagnostics and research applications. Their products allow flexible, reliable and affordable sensitization profiling of each patient. Their multidisciplinary team ensures that customers receive the most advanced tools to fulfill their diagnostic needs.

SunRegen is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. The company specializes in creating drugs aimed at treating a range of conditions, including neurological, neuromuscular, and ophthalmic disorders. Their initial product candidates are designed to target primary optical atrophy while also being evaluated for use in serious conditions such as ALS, Huntington's disease, Alzheimer's, and Parkinson's disease. SunRegen's approach is centered on delivering drug candidates with neuroprotective properties and promoting neurite outgrowth, which may offer favorable safety and tolerability profiles. The company is driven by a team of experienced professionals who have extensive backgrounds in drug development and clinical research across the pharmaceutical and technology sectors, all committed to delivering transformative treatments to patients in need.

Tarsio Medics is a company which specialises in investigating non-invasive methods to diagnose sleep disorders based on automatic image analysis Tarsio Medics has dedicated over 10 years of research in conjunction with the Pulmonology department of the Germans Trias i Pujol Hospital to create SleepWise. SleepWise is a system based on analysing the images recorded by a camera while a patient sleeps. SleepWise uses these images to perform an automatic OSAHS diagnosis and also to detect other sleep disorders.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

Allium Medical Solutions Ltd., based in Caesarea, Israel, specializes in the development, manufacturing, and marketing of minimally invasive medical devices. The company's portfolio includes a range of covered stents for various applications, such as ureteral, prostatic, and biliary conditions, as well as uro-gynecology products for tissue reinforcement and treatment of stress urinary incontinence. Additionally, Allium offers gastro-duodenal sleeves for managing diabetes and obesity, and the WIRION EPD system for embolic protection. These products are designed to enhance patient recovery and are used by healthcare professionals globally.

ViVO Smart Medical Devices specializes in the design and manufacturing of innovative medical devices aimed at enhancing patient care in the healthcare sector. The company holds an exclusive worldwide license for the Pupiloscope, a novel handheld device that facilitates real-time detection, assessment, and monitoring of pupil reactivity in patients with head trauma. In addition to developing proprietary products, ViVO offers a range of services including rapid prototyping, project management, testing, quality control, and full assembly. These services are tailored to support med-tech companies and clients in improving treatment outcomes and advancing healthcare solutions.

NovaGray is a biotechnology company focused on the development of advanced companion diagnostic tests designed to enhance radiation therapy planning. The company’s innovative biomarker-based tests evaluate patient sensitivity through a single blood sample, allowing healthcare practitioners to customize treatment doses and session sequences based on individual patient profiles. This personalized approach aims to improve patient outcomes while simultaneously reducing complications and overall treatment costs. By enabling physicians to tailor standard radiotherapy treatments to the specific sensitivities of patients, NovaGray seeks to significantly advance the efficacy of cancer care.

Oncoscanner is an oncological probe for intra-operative identification of cancerous tissues during surgical treatment for breast cancer.

Glucostratus Ltd is focused on developing and delivering digital solutions for remote blood glucose monitoring, targeting individuals with diabetes and healthcare professionals. Founded in 2005 and based in Helsinki, Finland, the company enables patients to share their glucose data with healthcare providers via a cloud platform, allowing for improved management of individual health outcomes. Glucostratus’s solutions include a software-as-a-service (SaaS) platform that facilitates easy access for doctors and nurses to patient results, as well as an Internet of Things (IoT) solution tailored for elderly diabetics who may lack technical skills. This comprehensive approach addresses the growing needs of the home care sector, ensuring that both patients and healthcare professionals can effectively monitor and manage diabetes treatment.

Scopio Labs Ltd. is a company based in Tel Aviv, Israel, that specializes in developing advanced digital microscopes utilizing computational imaging technology. Founded in 2015, Scopio Labs focuses on enhancing diagnostics in hematology by providing innovative tools that enable the analysis of blood samples and bone marrow aspirates. Its products are designed to deliver high-resolution imaging and actionable insights from large volumes of data, facilitating new diagnostic methods for blood-related diseases. The company's equipment supports clinical workflows by offering fully digital applications that improve the efficiency and accuracy of cell morphology assessments, thus enabling faster and more reliable detection and diagnosis of conditions such as cancer and other hematological disorders.

Tethis S.p.A. is an Italian company based in Milan that specializes in the development, manufacturing, and sale of in vitro diagnostic devices, particularly for fluorescent in situ hybridization (FISH) assays. Founded in 2004, Tethis operates within the bio- and nanotechnology sectors, offering a range of products, including a proprietary coated slide with microfluidic compartments, an automated slide staining system, and an instrument that facilitates key steps in the FISH protocol. The company's innovative diagnostic device enables the detection of circulating tumor cells through liquid biopsy, supporting early cancer diagnosis and personalized medicine. Tethis S.p.A. aims to improve clinical outcomes by providing tools for targeted therapy and monitoring minimal residual disease, thereby contributing to the advancement of healthcare solutions.

Xsensio is a digital health company focused on revolutionizing healthcare monitoring. It specializes in developing a wearable, Lab-on-Skin© platform that continuously analyzes biochemical data from the skin's surface in real-time, offering unprecedented insights into health and wellness.

BluSense Diagnostics, established in 2016, specializes in the development of innovative diagnostic systems for infectious diseases. The company combines advanced bioengineering from Scandinavia with top-tier Taiwanese hardware, software, and manufacturing expertise. Their flagship product is a consumer-oriented blood testing device that employs nanotechnology biosensing to deliver rapid results using just a single drop of blood. This enables users to monitor and manage virus outbreaks effectively.

Mermaid Care is a medical Technology firm that provides leading technology, care systems and solutions in optimizing the Ventilation Management within the Intensive Care Unit and Anaesthesia segment. Founded in 2006, the company has envisioned to be globally recognized amongst Key Opinion Leaders and Commercial Partners.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing microbiome therapies for gastrointestinal diseases. Established in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create treatments for conditions that disrupt the gut microbiota ecosystem, including clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome utilizes an innovative technology platform that facilitates the efficient development and production of defined, function-based microbiome therapies, enabling swift translation from research to clinical product readiness. The company's proprietary pipeline emphasizes the use of tailored, ecologically sound bacterial mixtures, distinguishing its approach from traditional fecal microbiota transplantation methods, thus offering a new standard for treating intestinal infections.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

Founded by a consultant ENT surgeon and designer entrepreneur, Cupris Ltd develops smartphone-connected medical devices for remote healthcare. Its flagship product is TYM, a smart otoscope that captures images and videos of the ear, enabling secure sharing via encrypted email. The company ensures data compliance with NHS standards.